Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment

Journal of Urology

Volumn 178, Issue 3 SUPPL., 2007, Pages

  Cooperberg, Matthew R ^a   Broering, Jeannette M ^a   Kantoff, Philip W ^a   Carroll, Peter R ^a  

^a Urologic Outcomes Research Group   (United States)

Author keywords

prognosis; prostate; prostatic neoplasms; questionnaires; risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CRYOTHERAPY; ELECTRON THERAPY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34547774187     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.135     Document Type: Article

References (19)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
2. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977
3. Wei J.T., Dunn R.L., Sandler H.M., McLaughlin P.W., Montie J.E., Litwin M.S., et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20 (2002) 557
4. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
5. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
6. D'Amico A.V. Combined-modality staging in predicting prostate-specific antigen outcome after definitive local therapy for men with clinically localized prostate cancer. Prostate Cancer: Principles and Practice (2002), Lippincott Williams & Wilkins, Philadelphia 254-268
7. Warlick C., Trock B.J., Landis P., Epstein J.I., and Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98 (2006) 355
8. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 24 (2006) 46
9. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141
10. Cooperberg M.R., Pasta D.J., Elkin E.P., Litwin M.S., Latini D.M., DuChane J., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (2005) 1938
11. Cooperberg M.R., Broering J.M., Litwin M.S., Lubeck D.P., Mehta S.S., Henning J.M., et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry. J Urol 171 (2004) 1393
12. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
13. Greene K.L., Meng M.V., Elkin E.P., Cooperberg M.R., Pasta D.J., Kattan M.W., et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). J Urol 171 (2004) 2255
14. Cooperberg M.R., Freedland S.J., Pasta D.J., Elkin E.P., Presti Jr. J.C., Amling C.L., et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 107 (2006) 2384
15. Smith E.B., Frierson Jr. H.F., Mills S.E., Boyd J.C., and Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?. Cancer 94 (2002) 2282
16. Terris M.K. Prostate biopsy strategies: past, present, and future. Urol Clin North Am 29 (2002)
17. Miller D.C., Gruber S.B., Hollenbeck B.K., Montie J.E., and Wei J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134
18. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., and Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 (2005) 1615
19. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco Jr. F.J., Dotan Z.A., Fearn P.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715